Breast Cancer 1, Early Onset (BRCA1) antibody

Antigen: Breast Cancer 1, Early Onset (BRCA1)

Synonyms: BRCA1, iris, pscp, brcai, brcc1, rnf53, brca1, LOC100224649, IRIS, PSCP, BRCAI, BRCC1, RNF53, BROVCA1, ARABIDOPSIS THALIANA BREAST CANCER SUSCEPTIBILITY1, ATBRCA1, breast cancer susceptibility1

Clonality: Monoclonal

Host: Mouse

Reactivity: Human

Conjugate: Un-conjugated

Application: Immunofluorescence (IF), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB), ELISA

Catalog no.: ABIN136329

Additional Information

Alternative name: BRCA1 / RNF53

Immunogen: Protein fragment expressed in E. coli corresponding to amino acids 762-1315.

Cross-Reactivity: Human

Isotype: IgG1

Description: BRCA1-17F8 recognizes full-length BRCA1, a 220kDa nuclear phosphoprotein, and does not recognize the ?exon 11 splice variant. In a high proportion of breast and ovarian cancer cell lines, BRCA1 aberrantly mislocates to the cytoplasm. Its usefulness to monitor functional inactivation of BRCA1 in sporadic breast cancers is under active investigation.

Specificity: This antibody does not recognize the delta exon 11 splice variant of BRCA1. In a high proportion of breast and ovarian cancer cell lines, BRCA1 aberrantly mislocates to the cytoplasm.

Application Details

Application Notes: For IF: Use at a concentration of 1 ug/ml. For WB: Use at 1-10 ug/ml. Predicted molecular weight: 208 kDa. For IHC-P: Use at an assay dependent dilution. Not tested in other applications. Optimal dilutions/concentrations should be determined by the researcher

Concentration: 1 mg/ml

Purification: Protein G affinity purified

Buffer: Phosphate-buffered saline, pH7.2 containing no preservatives

Restrictions: For Research Use only

Publications

Chen, Chen, Riley et al.: "Aberrant subcellular localization of BRCA1 in breast cancer." in: Science (New York, N.Y.), Vol. 270, Issue 5237, pp. 789-91, 1995 (PubMed).

Chen, Farmer, Chen et al.: "BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner." in: Cancer research, Vol. 56, Issue 14, pp. 3168-72, 1996 (PubMed).

Yoshikawa, Honda, Inamoto et al.: "Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 5, Issue 6, pp. 1249-61, 1999 (PubMed).

Altiok, Batt, Altiok et al.: "Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells." in: The Journal of biological chemistry, Vol. 274, Issue 45, pp. 32274-8, 1999 (PubMed).

Arizti, Fang, Park et al.: "Tumor suppressor p53 is required to modulate BRCA1 expression." in: Molecular and cellular biology, Vol. 20, Issue 20, pp. 7450-9, 2000 (PubMed).

Lu, Arrick: "Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms." in: Oncogene, Vol. 19, Issue 54, pp. 6351-60, 2001 (PubMed).

Bernard-Gallon, Dechelotte, Vissac et al.: "BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite." in: Breast cancer research : BCR, Vol. 3, Issue 1, pp. 61-5, 2001 (PubMed).

Zhong, Boyer, Chen et al.: "Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts." in: Cancer research, Vol. 62, Issue 14, pp. 3966-70, 2002 (PubMed).

Ongusaha, Ouchi, Kim et al.: "BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest." in: Oncogene, Vol. 22, Issue 24, pp. 3749-58, 2003 (PubMed).

Lee, Chew, Farmer et al.: "Biological functions of the BRCA1 protein." in: Breast disease, Vol. 10, Issue 1-2, pp. 11-22, 2005 (PubMed).